MLV & Co. Believes TGTX Won’t Stop Here

By George MacDonald

MLV & Co. analyst Arlinda Lee maintained a Buy rating on TG Therapeutics (NASDAQ: TGTX) today and set a price target of $22. The company’s shares opened today at $18.06, close to its 52-week high of $18.99.

Lee observed, “Last night, abstracts for the annual American Association of Cancer Research were released. Novel IRAK-4 inhibitors showed synergy with TGR-1202 and other agents to inhibit the growth of leukemic B-cell lines. In our view, the study highlights strategic possibilities for combinatorial therapies based on TGR-1202 and LGND/TGTX’s new IRAK-4 inhibitor program, which TGTX management recently indicated is on track to initiate clinical studies later this year. We continue to believe combination-based therapies represent the future for targeted cancer therapies and note that TGTX is well-positioned to capitalize on this. We maintain a BUY rating and $22/share PT”

Currently, the analyst consensus on TG Therapeutics is Strong Buy and the average price target is $25.67, representing a 42.1% upside. In a report issued on March 4, Roth Capital also maintained a Buy rating on the stock with a $33 price target.

Based on TG Therapeutics` latest earnings report from September 30, the company posted quarterly revenue of $38.1k and quarterly net profit of -$17.45M. In comparison, last year the company earned revenue of $38.1k and had a net profit of -$5.66M.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 13.0% and a 68.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Karyopharm Therapeutics, and Sorrento Therapeutics.

TG Therapeutics Inc is a biopharmaceutical company focused on the acquisition, development & commercialization of medically important pharmaceutical products for the treatment of cancer & other underserved therapeutic needs.